medicament "Perindopril-Darnitsa" is used at the following of indications:

• arterial hypertension;
• heart failure;
• prevention of a repeated stroke at patients with cerebrovascular diseases;
• prevention of cardiovascular complications at patients with documentary confirmed stable coronary heart disease.

Long-term treatment reduces risk of developing of a myocardial infarction and heart failure (by results of the research EUROPA).

Structure

Active ingredient: perindopril.

1 tablet contains 4 mg or 8 mg of a perindopril rub - to butylamine that corresponds to 3.338 mg 6.676 mg of a perindopril.

Excipients: lactose monohydrate; microcrystalline cellulose; silicon dioxide colloidal hydrophobic; magnesium stearate.

Contraindication

Hypersensitivity to active ingredient or to any of medicine excipients, or to the APF any other inhibitor.

Quincke's disease in the anamnesis after APF inhibitor use.

Idiopathic or hereditary Quincke's disease.

Co-administration with the medicines containing active ingredient aliskiren, to patients, sick diabetes or a renal failure (SKF <60 ml/min. / 1.73м ² ).

Pregnancy or period of planning of pregnancy.

Simultaneous use with sakubitrilom/valzartany.

Extracorporal methods of treatment which lead to contact of blood with negatively charged surfaces.

Considerable bilateral stenosis of renal arteries or stenosis of an artery of the only kidney.

Route of administration and doses

For oral administration.

Tablet "Perindopril-Darnitsa" on 4 mg and 8 mg can halve 2 mg and 4 mg for achievement of a dose.

recommends to take the Pill 1 time a day in the morning before food.

Dose to select

individually, depending on indicators of arterial blood pressure.

Arterial hypertension.

Perindopril's

rubs - it is possible to appoint butylamine as monotherapy or in a combination with medicines of other classes of antihypertensive drugs.

Recommended initial dose makes 4 mg of 1 times a day in the morning.

Patients with high activity of RAAS (especially patients with renovascular hypertensia, disturbance of water and electrolytic balance, a warm decompensation or heavy hypertensia) can test an excessive lowering of arterial pressure after reception of the first dose. Such patients are recommended to begin treatment with a dose of 2 mg and to spend the beginning of therapy under observation of the doctor.

Dose can be raised to 8 mg of 1 times a day in 1 month of treatment.

at the beginning of use of a perindopril rubs - butylamine possibly developing of symptomatic arterial hypotension; it is probable at patients who at the same time accept diuretics. To such patients it is necessary to begin treatment perindoprily with care as they can have a deficiency of water and/or salt.

If it is possible

, it is necessary to stop intake of diuretics in 2-3 days prior to therapy of a perindopril rubs - butylamine.

to Patients with arterial hypertension which cannot stop use of diuretics treatment should begin with

with a dose 2 mg. At such patients it is necessary to control function of kidneys and level of potassium in blood serum. Further increase in a dose of a perindopril rubs - butylamine it is necessary to carry out depending on indicators of arterial blood pressure. In case of need therapy by diuretic can be restored.

to Patients of advanced age treatment should begin with

with a dose 2 mg which can be raised to 4 mg in 1 month of treatment, and then, in case of need, to 8 mg taking into account function of kidneys.

Heart failure.

to

to Patients with heart failure which the perindoprila rubs - butylamine usually follows appoint along with diuretic that potassium removes, and/or digoxin and/or β-blockers, treatment is recommended to be begun under careful control and with an initial dose of 2 mg which should be accepted in the morning. In 2 weeks on condition of good tolerance to raise a dose to 4 mg of 1 times a day. To select a dose individually, depending on a clinical condition of the patient.

to Patients with heavy heart failure and to other patients from group of high risk (patients with renal failures and a tendency to disturbances of level of electrolytes, patients who receive simultaneous therapy by diuretics and/or vazodilatator) treatment should be begun with

under careful control.

should carry out by

At patients with high risk of developing of symptomatic arterial hypotension (patients with deficiency of electrolytes, with a hyponatremia or without it, patients with a hypovolemia or those who received intensive care by diuretics) correction of the specified states if it is possible, before prescription of medicine. Arterial blood pressure, function of kidneys and level of potassium in blood serum need to be controlled carefully both to, and during treatment.

Prevention of a repeated stroke at patients with cerebrovascular diseases.

Recommended initial dose makes 2 mg (½ tablets of Perindopril-Darnitsa medicine of 4 mg) of 1 times a day in the morning. After 2 weeks of treatment to increase a dose to 4 mg (1 tablet of Perindopril-Darnitsa medicine of 4 mg) of 1 times a day in the morning.

If after 2 weeks of use of Perindopril-Darnitsa medicine of 4 mg the patient needs additional control of arterial blood pressure, it is possible to appoint indapamid in a dose 1 tablet a day. Treatment can be begun at any time in time from 2 weeks to several years after primary stroke.

Prevention of cardiovascular complications at patients with documentary confirmed stable coronary heart disease.

Treatment to begin with

with Perindopril-Darnitsa medicine 4 mg (1 tablet a day, in the morning). In 2 weeks on condition of good tolerance and taking into account function of kidneys the dose should be raised to 8 mg.

to Patients of advanced age treatment should begin with

with a dose 2 mg (½ tablets of Perindopril-Darnitsa medicine of 4 mg) of 1 times a day, in the morning, in a week a dose to raise to 4 mg (1 tablet of Perindopril-Darnitsa medicine of 4 mg) in 2 weeks taking into account function of kidneys a dose to raise to 8 mg (Perindopril-Darnitsa 8 mg, 1 tablet a day). Increase in a dose is possible only on condition of good tolerance of the previous dose.

Feature of use

Children

to children did not study Efficiency and safety of use of medicament therefore the perindoprila rubs - children are not recommended to appoint butylamine.

Pregnant

Medicine the pregnant women or women planning pregnancy cannot apply

.

Drivers

Perindopril rubs - butylamine does not show direct impact on ability to run vehicles or to work with other mechanisms. But some patients can have individual reactions connected with a lowering of arterial pressure, especially in an initiation of treatment or at simultaneous use with other antihypertensive medicines. As the result, ability to run vehicles or work with other mechanisms can be reduced.

Overdose

perindoprit

Information on overdose insufficiently. The symptoms connected with overdose of APF inhibitors are possible: arterial hypotension, circulator shock, disturbance of electrolytic balance, renal failure, hyperventilation, tachycardia, palpitation, bradycardia, dizziness, uneasiness, cough and so forth.

to

At overdose recommends administration of solution of sodium of chloride of 0.9% (9 mg/ml). In case of developing of arterial hypotension the patient needs to accept horizontal position with a low headboard. Whenever possible it is necessary to provide to the patient of infusion of angiotensin II and/or introduction of catecholamines. Perindopril it is possible to remove from system blood circulation by means of a hemodialysis. In case of developing of bradycardia, resistant to treatment, the use of an artificial pacemaker is shown. It is necessary to establish continuous monitoring of key indicators of activity, concentration of electrolytes and creatinine in blood serum.

Side reactions

Profile of safety of a perindopril corresponds to a profile of safety of APF inhibitors.

Most frequent side reactions which were observed at use of a perindopril in the course of clinical trials: dizziness, a headache, paresthesias, vertigo, a disorder of vision, a ring in ears, arterial hypotension, cough, an asthma, an abdominal pain, a constipation, diarrhea, a food faddism (dysgeusia), dyspepsia, nausea, vomiting, an itching, skin rashes, myotonia, an asthenia.

Storage conditions

to Store

in original packing at a temperature not above 25 °C. To store out of children's reach.

Expiration date - 2 years.